CClinicalTrials.gg
Sign In
Not yet recruitingNCT07852858Updated Oct 5, 2026

Supporting Families In Coping With Parental Cancer: A Multi-Site Randomized Controlled Trial

An interventional study of Parent Support Intervention in Cancer, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

Updated Oct 5, 2026Start date movedEligibility revised+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this behavioral research study is to learn about the effect of a parent support intervention on cancer patients' and their family caregivers' mental wellbeing, and family functioning.

Read the detailed description

Primary Objectives:

  1. Examine the efficacy of the parent support intervention in improving patient anxiety symptoms (primary outcome), family anxiety symptoms (secondary outcomes) and patient and family depressive symptoms (exploratory outcome).
  2. Determine whether the parent support intervention improves family function (i.e., cancer-related parenting, family cohesion and parent-child communication) relative to the UC group, which in turn improves primary and secondary outcomes.
  3. Explore if the parent intervention improves patient end of life quality care and psychological adjustment in bereaved families using a mixed-method approach.
02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 400 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patients:

  1. Diagnosed with a metastatic (stage IV) breast, thoracic, gastrointestinal, gynecologic, or genitourinary cancer
  2. With at least one dependent child between the ages of 4 and 17 years and currently living with the parent
  3. ECOG performance status of ≤ 2
  4. With a spousal caregiver/partner who co-parents the child(ren) OR a family caregiver who offers care and support to both the patient and the child(ren) as determined by the patient.

Patients and Caregivers:

  1. At least 18 years old;
  2. Able to read and speak English and/or Spanish.

Exclusion criteria

Exclusion Criteria:

  1. Experiences cognitive deficits that would impede the completion of self-report instruments and intervention engagement as deemed by their attending oncologist per medical notes and/or patient not being oriented to time, place and person during the recruitment process
  2. Regularly (self-defined) participation in individual, couple and/or family psychotherapy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    CTL: Patients Receive Cancer Treatment Per Usual Care (UC) Control Group

    Behavioral: Parent Support Intervention

  • No intervention
    INTERV: Parent - Caregiver Dyads TO The Parent Support Intervention

Interventions

  • BehavioralParent Support Intervention

    Participants will receive one 60 min. session per week for 6 weeks (4 sessions, 240 min. total).

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
  • UT MD Anderson
    Houston, Texas 77030, United States
    • Kathrin Milbury, MA, PHD · Contact · kmilbury@mdanderson.org · 713-745-2868
    • Kathrin Milbury, MA, PHD · Principal investigator
08

References and documents

09

Updates

2 registry updates since Sep 25, 2026
Start date
Mar 1, 2027→Dec 1, 2026
Oct 5, 2026
Also revised
eligibility
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 5, 2026
    Start date Mar 1, 2027→Dec 1, 2026
    Eligibility Criteria revised
    + 1 other change: description
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852858
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 30, 2031 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Oct 5, 2026

Study contacts

Kathrin Milbury, MA, PHD
Contact
kmilbury@mdanderson.org
(713) 745-2868
Kathrin Milbury, MA, PHD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion